EAGLE POINT STRATEGIES LLC

Lobbying for OBJECT PHARMA · Biopharma company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $10,000.00 income · posted Jan 14, 2026

Lobbying activity 2

Veterans

Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.

Health Issues

Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.